Senzime AB (publ) (STO:SEZI)

Market Cap	660.30M -8.0%
Revenue (ttm)	104.02M +77.9%
Net Income	-137.42M
EPS	-0.93
Shares Out	157.22M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	340,917
Average Volume	202,225
Open	4.285
Previous Close	4.290
Day's Range	4.140 - 4.335
52-Week Range	3.600 - 7.380
Beta	0.29
RSI	42.41
Earnings Date	Apr 22, 2026

About Senzime AB

Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue’s opposition to carrying an alternating electrical current. It also pr...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1999
• Employees: 54
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SEZI

Financial Performance

In 2025, Senzime AB's revenue was 104.02 million, an increase of 77.89% compared to the previous year's 58.48 million. Losses were -137.42 million, 15.7% more than in 2024.